Rockmed Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 23-10-2024
- Paid Up Capital ₹ 0.50 M
as on 23-10-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.30 Cr
as on 23-10-2024
- Revenue 30.54%
(FY 2023)
- Profit 31.46%
(FY 2023)
- Ebitda -392.26%
(FY 2023)
- Net Worth 44.94%
(FY 2023)
- Total Assets 54.68%
(FY 2023)
About Rockmed Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.30 Cr.
Shaheer Ariz and Yashpal Arora serve as directors at the Company.
- CIN/LLPIN
U24100DL2013PTC253085
- Company No.
253085
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 May 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Rockmed Pharma Private Limited offer?
Rockmed Pharma Private Limited offers a wide range of products and services, including Skin Care, Bath Essentials, Facewash, Sunscreen Products.
Who are the key members and board of directors at Rockmed Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shaheer Ariz  | Director | 29-May-2013 | Current |
| Yashpal Arora | Director | 29-May-2013 | Current |
Financial Performance of Rockmed Pharma.
Rockmed Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 30.54% increase. The company also saw a substantial improvement in profitability, with a 31.46% increase in profit. The company's net worth Soared by an impressive increase of 44.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rockmed Pharma?
In 2023, Rockmed Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indisurg (India) Surgicals LlpActive 4 years 6 monthsShaheer Ariz and Yashpal Arora are mutual person
- Kureasia Pharma Private LimitedActive 9 years 11 days
Shaheer Ariz and Yashpal Arora are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Jun 2024 | ₹1.30 Cr | Open |
How Many Employees Work at Rockmed Pharma?
Rockmed Pharma has a workforce of 18 employees as of Aug 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rockmed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rockmed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
